Cephalosporin C acylase

ABSTRACT

A cephalosporin C acylase from Pseudomonas diminuta N-176 is characterized by its ability to catalyze the conversion of cephalosporin C, glutaryl 7-ACA, adipyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin, N-benzoylcephalosporin C and cephalothin into 7-aminocephalosporanic acid. The enzyme contains an α-subunit having a molecular weight of 26 kDA and a β-subunit having a molecular weight of 58 kDa. A method for the recombinant production of the present cephalosporin C acylase in Escherichia coli is provided.

The present application is a divisional of pending application Ser. No. 07/747,901, filed on Aug. 20, 1991, allowed.

The invention relates to a new cephalosporin C acylase (hereinafter referred to as "CC acylase N-176"). More particularly, it relates to a new CC acylase derived from Pseudomonas diminuta N-176, a DNA encoding thereof, an expression vector containing said DNA, a microorganism transformed with said expression vector, and the production of the CC acylase by culturing said transformant.

Cephalosporin C acylase is a general term for an enzyme, which is, in common, capable of hydrolyzing cephalosporin C to 7-aminocephalosporanic acid (7-ACA). 7-ACA has been made by methods of chemical conversion of cephalosporin C such as iminoether or nitrosyl chloride method. However, to make cost reduction, an alternative method utilizing enzymatic conversion has been searched for a long time since similar enzymatic conversion was successfully adopted for the production of 6-aminopenicillanic acid (6-APA) which is a starting material for penicillins, another family of β-lactam antibiotics. In the course of such efforts, two step enzymatic conversion was devised using D-amino acid oxidase and glutaryl 7-ACA (GL 7-ACA) acylase. This method has been industrialized as the one where the enzymatic oxidation was substituted by chemical oxidation. This two step method was an offspring to overcome the difficulty of discovering acylases which can convert cephalosporin C directly to 7-ACA.

However, since advantage of one step conversion over the two step one was apparent, extensive studies for searching such an enzyme named cephalosporin C acylase has still been continued thereafter. Recently, cephalosporin C acylases were definitely clarified to be produced by Pseudomonas species (Cf. Japanese Patent Applications Laid Open Nos. 61-152286 and 62-48380).

The inventors of this invention have conducted extensive studies for searching new CC acylases, and as the results, the present inventors have been found a new characteristic CC acylase N-176 in the cultured broth of a newly isolated organism, Pseudomonas diminuta N-176 and established industrial production of this enzyme. The CC acylase N-176 of this invention, as compared with prior CC acylases, is characterized by higher stability, higher enzymatic potency and the like, and further characteristics of this CC acylase will be apparent from the description mentioned below.

A strain named Pseudomonas diminuta N-176 which is a cephalosporin C acylase producer was newly isolated from a soil sample collected in Aomori Prefecture, Japan. A culture of the living organism has been deposited with Fermentation Research Institute, Agency of Industrial Science and Technology, 1-3, Higashi 1 chome Tsukubashi Ibaraki-ken 305 Japan under the number FERM-BP 3046 on Aug. 7, 1990.

Pseudomonas diminuta N-176 has the following morphological and physiological characteristics and identified as Pseudomonas diminuta according to Bergey's Manual of Systematic Bacteriology (Volume 1) and in the result of the comparative experiment using Pseudomonas diminuta ATCC 19146. The method described in Bergey's Manual was employed principally for this taxonomic study.

1. Morphological Characteristics

Morphological observation of the strain N-176 was carried out by the optical microscope with cells grown in Trypticase soy broth (BBL Co., Ltd., U.S.A.) at 37° C.

Strain N-176 was a gram-negative, motile bacterium. The cell shapes were rod. Results are shown in Table 1.

                  TABLE 1                                                          ______________________________________                                         Morphological characteristics of strain N-176                                  ______________________________________                                         Gram stain        negative                                                     color of colony   gray                                                         cell shape        rod                                                          spore             negative                                                     motility          positive                                                     flagella          single polar flagellum                                       ______________________________________                                    

2. Physiological Characteristics

Physiological characteristics of the strain N-176 were summarized in Table 2.

The strain N-176 was oxidase positive, catalase positive and O-F test negative. Gelatin was not liquefied and esculin hydrolysis was negative. None of the carbohydrates tested were fermented. Indole test was negative. Voges-Proskauer test was negative.

                  TABLE 2                                                          ______________________________________                                         Physiological characteristics of the                                           strain N-176                                                                   Conditions        Characteristics                                              ______________________________________                                         growth                                                                         in air            +                                                            in anaerobe       -                                                            at 8° C.   -                                                            at 30° C.  +                                                            at 37° C.  +                                                            at 40° C.  -                                                            pigment           -                                                            catalase          +w                                                           oxidase           +w                                                           OF-tst            -                                                            TSI               -/-                                                          IPA               -                                                            H.sub.2 S (SIM medium)                                                                           -                                                            H.sub.2 S (lead acetate)                                                                         -                                                            indole            -                                                            VP                -                                                            Simmons' citrate  -                                                            urease (Christensen)                                                                             +w                                                           gelatin liquefection                                                                             -                                                            esculin hydrolysis                                                                               -                                                            nitrate reduction/gas                                                                            +/-                                                          lysine decarboxylase                                                                             -                                                            ornithine decarboxylase                                                                          -                                                            arginine dihydrolase                                                                             -                                                            acylamidase       -                                                            utilization of                                                                 arabinose         -                                                            dulcitol          -                                                            glucose           -                                                            galactose         -                                                            ethanol           -                                                            inositol          -                                                            lactose           -                                                            maltose           -                                                            mannose           -                                                            rhamnose          -                                                            starch            -                                                            sucrose           -                                                            trehalose         -                                                            xylose            -                                                            lecithinase (egg yolk)                                                                           -                                                            ______________________________________                                          Note:                                                                          +; positive,                                                                   -; negative,                                                                   +w; weakly positive                                                      

The new CC acylase of this invention has the following characteristics.

Namely, the new CC acylase of this invention

(a) has ability to catalyze the enzymatic conversion of cephalosporin C, glutaryl 7-ACA, adipyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin C, N-benzoylcephalosporin C and cephalothin into 7-amino cephalosporanic acid,

(b) is composed of α-subunit [Molecular weight: 26,000 dalton (SDS-PAGE)] and β-subunit [Molecular weight: 58,000 dalton (SDS-PAGE)] and

(c) has N-terminal amino acid sequence (SEQ ID NO:1) of the o-subunit: Thr-Met-Ala-Ala-Asn-Thr-Asp-Arg-Ala-Val-Leu-Gln-Ala-Ala-Leu-Pro-Pro-Leu-.

The new CC acylase of this invention can be prepared by recombinant DNA technology, polypeptide synthesis and the like.

Namely, the new CC acylase can be prepared by culturing a host cell transformed with an expression vector comprising DNA encoding amino acid sequence of the new CC acylase in a nutrient medium and recovering the new CC acylase from the cultured broth.

In this process, particulars of which are explained in more detail as follows.

The host cell may include microorganisms [bacteria (e.g. Escherichia coli, Bacillus subtills, etc.), yeast (e.g. Saccharomyces cerevisiae, etc.), animal cell lines and cultured plant cells]. Preferred examples of the microorganism may include bacteria, especially a strain belonging to the genus Escherichia (e.g. E. coli JM109 ATCC 53323, E. coli HB101 ATCC 33694, E. coli HB101-16 FERM BP-1872, E. coli 294 ATCC 31446, etc.), yeast, especially a strain belonging to the genus Saccharomyces [e.g. Saccharomyces cerevisiae AH22], animal cell lines [e.g. mouse L929 cell, Chinese hamster ovary (CHO) cell etc.]and the like.

When bacterium, especially E. coli is used as a host cell, the expression vector is usually composed of at least promoter-operator region, initiation codon, DNA encoding amino acid sequence of the new CC acylase, termination codon, terminator region and replicatable unit. When yeasts or animal cells are used as host cells, the expression vector is preferably composed of at least promoter, initiation codon, DNA encoding amino acid sequences of the signal peptide and the ne CC acylase and termination codon, and it is possible that enhancer sequence, 5'- and 3'-noncoding region of the new CC acylase, splicing junctions, polyadenylation site and replicatable unit are also inserted into the expression vector.

The promoter-operator region comprises promoter, operator and Shine-Dalgarno (SD) sequence (e.g. AAGG, etc.). Preferable promoter-operator region may include conventionally employed promoter-operator region (e.g. PL-promoter and trp-promoter for E. coli) and promoter of the CC acylase N-176 chromosomal gene. The promoter for expression of the new CC acylase in yeast may include the promoter of the TRPl gene, the ADHI or ADHII gene and acid phosphatase (pH05) gene for S. cerevisiae and the promoter for expression of the new CC acylase in mammalian cells may include SV40 early or late-promoter, HTLV-LTR-promoter, mouse metallothionein I(MMT)-promoter, vaccinia-promoter and the like.

Preferable initiation codon may include methionine codon (ATG).

The signal peptide may include a signal peptide of conventionally employed other enzymes (signal peptide of the native t-PA, signal peptide of the native plasminogen) and the like.

The DNA encoding amino acid sequence of the signal peptide or the new CC acylase can be prepared in a conventional manner such as a partial or whole DNA synthesis using DNA synthesizer and/or treatment of the complete DNA sequence coding for the new CC acylase inserted in a suitable vector [e.g. PCCN 176-2]obtainable from a transformant [e.g. E. coli JM109 (PCCN 176-2) FERM BP-3047]with a suitable enzyme (e.g. restriction enzyme, alkaline phosphatase, polynucleotide kinase, DNA ligase, DNA polymerase, etc.).

The termination codon(s) may include a conventionally employed termination codon (e.g. TAG, TGA, etc.).

The terminator region may include natural or synthetic terminator (e.g. synthetic fd phage terminator, etc.).

The replicatable unit is a DNA compound having capable of replicating the whole DNA sequence belonging thereto in a host cell and may include natural plasmid, artificially modified plasmid (e.g. DNA fragment prepared from natural plasmid) and synthetic plasmid and preferable examples of the plasmid may include plasmid pBR322 or artificially modified thereof (DNA fragment obtained from a suitable restriction enzyme treatment of pBR322) for E. coli, yeast 2μ plasmid or yeast chromosomal DNA for yeast, plasmid pRSVneo ATCC 37198, plasmid pSV2dhfr ATCC 37145, plasmid pdBPV-MMTneo ATCC 37224, plasmid pSV2neo ATCC 37149 for mammalian cells.

The enhancer sequence may include the enhancer sequence (72 b.p.) of SV40.

The polyadenylation site may include the polyadenylation site of SV40.

The splicing junction may include the splicing junction of SV40.

The promoter, initiation codon, DNA encoding amino acid sequence of the new CC acylase, termination codon(s) and terminator region can consecutively and circularly be linked with an adequate replicatable unit (plasmid) together, if desired, using an adequate DNA fragment(s) (e.g. linker, other restriction site, etc.) in a conventional manner (e.g. digestion with restriction enzyme, ligation using T4 DNA ligase) to give an expression vector. When mammalian cells are used as host cells, it is possible that enhancer sequence, promoter, 5'-noncoding region of the cDNA of the new CC acylase, initiation codon, DNA encoding amino acid sequences of the signal peptide and the new CC acylase, termination codon(s), 3'-noncoding region of the cDNA of the new CC acylase, splicing junctions and polyadenylation site are consecutively and circularly be liked with an adequate replicatable unit together in the above manner.

A host cell can be transformed (transfected) with the expression vector. Transformation (transfection) can be carried out in a conventional manner [e.g. Kushner method for E. coli, calcium phosphate method for mammalian cells, microinjection, etc.] to give a transformant (transfectant).

For the production of the new CC acylase in the process of this invention, thus obtained transformant comprising the expression vector is cultured in an aqueous nutrient medium.

The nutrient medium may contain carbon source(s) (e.g. glucose, glycerine, mannitol, fructose, lactose, etc.) and inorganic or organic nitrogen source(s) (e.g. ammonium sulfate, ammonium chloride, hydrolysate of casein, yeast extract, polypeptone, bactotrypton, beef extract, etc.). If desired, other nutritious sources [e.g. inorganic salts (e.g. sodium or potassium biphosphate, dipotassium hydrogen phosphate, magnesium chloride, magnesium sulfate, calcium chloride), vitamins (e.g. vitamin B₁), antibiotics (e.g. ampicillin, kanamycin), etc.] may be added to the medium. For the culture of mammalian cells, Dulbecco's Modified Eagle's Minimum Essential Medium (DMEM)supplemented with fetal calf serum and an antibiotic is often used.

The culture of the transformant (including transfectant) may usually be carried out at pH 5.5-8.5 (preferably pH 7-7.5) and 18°-40° C. (preferably 25°-38° C.) for 5-50 hours.

When thus produced new CC acylase exists in the culture solution, culture filtrate (supernatant) is obtained by filtration or centrifugation of the cultured broth. From the culture filtrate, the new CC acylase can be purified in a conventional manner as generally employed for the purification and isolation of natural or synthetic proteins (e.g. dialysis, gel filtration, affinity column chromatography using anti-CC acylase monoclonal antibody, column chromatography on a suitable adsorbent, high performance liquid chromatography, etc.). When the produced new CC acylase exists in periplasm and cytoplasm of the cultured transformant, the cells are collected by filtration and centrifugation, and the cell wall and/or cell membrane thereof are destroyed by, for example, treatment with super sonic waves and/or lysozyme to give debris. The debris can be dissolved in a suitable aqueous solution (e.g. 8M aqueous urea, 6M aqueous guanidium salts). From the solution, the new CC acylase can be purified in a conventional manner as exemplified above.

if it is necessary to refold the new CC acylase produced in E. coli, the refolding can be carried out in a conventional manner.

This invention further provides a process for the preparation of a compound of the formula: ##STR1## wherein R¹ is acetoxy, hydroxy and hydrogen or its salt, which comprises contacting a compound of the formula: ##STR2## wherein R¹ is the same as defined above and R² is carboxylic acyl, or its salt, with the cultured broth of a microorganism transformed with an expression vector comprising DNA encoding the new CC acylase of this invention or its processed material.

The carboxylic acyl for R² may include aliphatic, aromatic or heterocyclic carboxylic acyl and suitable example thereof may be C₁ -C₆ alkanoyl which may have one or two suitable substituent(s) selected from the group of amino, carboxy, C₁ -C₆ alkanoylamino, benzamido or thienyl suitable salt of the compounds (I) and (II) may be alkali metal salt (e.g. sodium salt, potassium salt).

If the CC acylase activity usually exists in transformed cells, the following preparations can be exemplified as a processed material of the cultured broth.

(1) Raw cells; separated from the cultured broth in conventional manners such as filtration and centrifugation

(2) dried cells; obtained by drying said raw cells in conventional manners such as lyophilization and vacuum drying

(3) cell-free extract; obtained by destroying said raw or dried cells in conventional manners (e.g. autolysis of the cells using an organic solvent, grinding the cells with alumina, sea sand, etc. or treating the cells with super sonic waves)

(4) enzyme solution; obtained by purification or partial purification of said cell-free extracts in conventional manners (e.g. column chromatography)

(5) immobilized cells or enzyme; prepared by immobilizing said cells or enzyme in conventional manners (e.g. a method using acrylamide, glass bead, ion exchange resin, etc.).

The reaction comprising a contact of the compound (II) with the enzyme can be conducted in an aqueous medium such as water or a buffer solution, that is, it can be usually conducted by dissolving or suspending the cultured broth or its processed material in an aqueous medium such as water or a buffer solution containing the compound (II).

Preferable pH of the reaction mixture, concentration of the compound (II), reaction time and reaction temperature may vary with properties of a cultured broth or its processed material to be used. Generally, the reaction is carried out at pH 6 to 9, preferably pH 7 to 9, at 5° to 40° C., preferably 5° to 37° C. for 2 to 50 hours.

The concentration of the compound (II) as a substrate in the reaction mixture may be preferably selected from a range of 1 to 100 mg/ml.

Thus produced compound (I) can be purified and isolated from the reaction mixture in a conventional manner.

Brief explanation of the accompanying drawings is as follows.

FIG. 1 shows restriction site and function map of plasmids pCCN 176-1, pCCN 176-2 and pCCN 176-3. In this Figure, the abbreviation "MCS" means multiple cloning site.

FIGS. 2-1 thru 2-6 show nucleotide sequence (SEQUENCE ID NO:2) and deduced amino acid sequence (SEQUENCE ID NO:3) of the CC acylase N-176 chromosomal gene. In the numbering of the DNA, the first nucleotide of the coding region is designated as +1.

FIG. 3 shows optimum temperature of the CC acylase N-176.

FIG. 4 shows thermostability of the CC acylase N-176.

FIGS. 5a and b show optimum pH of the CC acylase N-176.

FIG. 6 shows pH profile of stability of the CC acylase N-176.

FIGS. 7a and b show inhibition of GL-7ACA acylase activity of the CC acylase N-176 by reaction products.

FIGS. 8a and b shows inhibition of cephalosporin C acylase activity of the CC acylase N-176 by reaction products.

In the following Examples, some plasmids, enzymes, such as restriction enzymes, T4 DNA ligases, and other materials were obtained from commercial sources and used according to the indication by suppliers. Operations employed for the cloning of DNA, transformation of host cells, cultivation of transformants, recovery of the new CC acylase from the cultured broth, and the like are well known in the art or can be adapted from literatures.

Following examples are given for the purpose of illustrating this invention, but not limited thereto

EXAMPLE 1 Isolation of the gene encoding cephalosporin C acylase of Pseudomonas diminuta N-176 1.1 Preparation of chromosomal DNA of Pseudomonas diminuta N-176

Chromosomal DNA of Pseudomonas diminuta N-176 was prepared according to the method of Harris-Warrick et al., Proc. Natl. Acad. Sci., USA 72: 2207-2211, 1975. Pseudomonas diminuta N-176 was grown with shaking at 30° C. for 40 hours in 3 l of meat extract broth (polypeptone 0.5%, sodium glutamate 0.5%, meat extract 0.2%, MgSO₄.7H₂ O 50 μg/ml), harvested by centrifugation and washed once with 50 mM Tris-HCl (pH 8) containing 1 mM EDTA. Resultant cell pellets [approximately 5 g (wet weight)] was suspended in 12.5 ml of 50 mM Tris-HCl (pH 8) containing 20% sucrose and 1 mM EDTA and treated with 12.5 mg of lysozyme at 37° C. for 15 min. Furthermore, to this suspension, 30 ml of 100 mM EDTA (pH 9.6)-1% lauroyl sarcosylate and 10 ml of 5 mg/ml of pronase E were added and the resultant mixture was incubated at 50° C. for 2 hours. After addition of 1.25 g of CsCl to each 1 ml of the lysate, it was applied to equilibrium density gradient centrifugation. After centrifugation, chromosomal DNA fractions were pooled and dialyzed against 10 mM Tris-HCl (pH 8) containing 1 mM EDTA (TE buffer).

1.2. Construction of genomic DNA library of Pseudomonas diminuta N-176

Three hundred micrograms of chromosomal DNA of Pseudomonas diminuta N-176 was partially cleaved with 3.75 units of restriction endonuclease Sau3AI and the resultant DNA fragments were applied to a GEN-PAK DNA column (6.0 mm×50 mm, Waters, USA) and elution was performed with a linear gradient of NaCl (0.07-0.1M) in 25 mM phosphate buffer (pH 6) at a flow rate of 1.0 ml/min over 30 min. Fractions of DNA with an average size of 7-9 kilo bases (kb) were pooled and DNA was collected by ethanol precipitation and dissolved in TE buffer. 20 μg of the plasmid vector pHSG298 DNA (Takara Shuzo, Japan) was cleaved with BamHI (Takara Shuzo, Japan), followed by phenol extraction and ethanol precipitation. The DNA was dissolved in 200 μl of 10 mM Tris-HCl (pH 8) containing 10 mM EDTA and incubated at 37° C. for 20 min with 1 unit of bacterial alkaline phosphatase (Takara Shuzo, Japan). The reaction mixture was treated with phenol extraction and ethanol precipitation and dissolved in 40 μl of TE buffer. Sau3AI partially cleaved chromosomal DNA fragments (20 μg) were ligated at 12° C. for 16 hours with 500 units of T4 DNA ligase (Takara Shuzo, Japan) to 5 μg of the linearized and dephosphorylated pHSG298. The ligation mixture was used for transformation of E. coli JM109 (Toyobo Co., Ltd., Japan). Transformation was performed according to the procedure of D. Hanahan (Cf. J. Mol. Biol. 166, 557-580 (1983)). The transformants were selected on LM agar containing trypton (Difco) 1%, yeast extract (Difco) 0.5%, sodium chloride 10 mM, magnesium sulfate 10 mM, agar 1.5% and 20 μg of kanamycin /ml The number of transformants obtained was 24,000.

1.3. Selection of a Clone Possessing a Plasmid Containing a Cephalosporin C Acylase Gene

A clone possessing a plasmid containing cephalosporin C acylase gene was screened among the genomic DNA library of Pseudomonas diminuta N-176 by the following HPLC method. Transformant colonies were picked up and grown overnight at 30° C. in 1 ml of 2% Bouillon (Eiken Chemical Co., Ltd., Japan) supplemented with 1 mM isopropyl-β-D-galactoside (IPTG: Sigma Chemical Co., Ltd., U.S.A.). Cells were harvested by centrifugation and resulting cell pellets were used for assay. Reaction mixture (200 μl) containing 100 mM phosphate (pH 8), 2 mg of GL-7ACA or cephalosporin C Na and cell pellets were thoroughly mixed and incubated for 10 min at 37° C. The reaction was terminated by the addition of 200 μl of 4% acetic acid. Samples were applied to a Inertsil ODS-2 column (4.6 mm×150 mm)(Gasukuro Kogyo Co., Ltd., Japan) and elution was performed with 0.567 g/l of Na₂ PO₄, 0.36 g/l of KH₂ PO₄ and 2-4% methanol. 7ACA was detected with absorption at 254 nm.

1.4. Subcloning of the Gene Encoding Cephalosporin C Acylase (Cf. FIG. 1)

Plasmid DNA was extracted from one of the positive clones by the cleared lysate method described by Clewell and Helinski (Cf. Proc. Natl. Acad. Sci., USA 61: 1159-1166, 1969) and named pCCN176-1. The size of the insert DNA was estimated to h=approximately 8 kb by agarose gel electrophoresis. 10 μg of the recombinant plasmid pCCN176-1 DNA was cleaved with KpnI (Takara Shuzo, Japan) and 4 kb of the resulting DNA fragment of the insert was separated by agarose gel electrophoresis, eluted from the gel by electrophoresis, treated with phenol extraction and ethanol precipitation and dissolved in TE buffer. This DNA fragment of the insert of 1 μg was ligated with 25 units of T4 DNA ligase to 1 μg of pHSG299 DNA (Takara) linearized by digestion with KpnI. E. coli JM109 was transformed with this ligation mixture Transformants were selected on LM agar plates containing 20 μg/ml of kanamycin and confirmed by criteria of loss of β-galactosidase activity, size of an insert and presence of cephalosporin C acylase. Activity of cephalosporin C acylase was measured by the HPLC method as described in Example 1.3. From one of the recombinant strain, plasmid DNA was extracted by the cleared lysate method and named pCCN176-2. 15 μg of pCCN176-2 was cleaved with EcoRI (Takara Shuzo, Japan), treated with phenol extraction and ethanol precipitation and dissolved in 336 μl of Ba131 buffer (20 mM Tris-HCl (pH 8), 600 mM NaCl, 12 mM CaCl₂, 12 mM MgCl₂ and 1 mM EDTA). This linearized DNA was incubated at 30° C. with 30 units of Ba131 nuclease. Fifty μl of aliquots were sampled after 30 sec, 1, 2, 3, 4 and 5 min of incubation and the reaction was stopped by adding equal volume of phenol. After treatment of phenol and ethylether extraction and ethanol precipitation, Ba131 treated DNAs were dissolved in 20 mM Tris-HCl (pH 7.5) containing 10 mM MgCl₂ and 1 mM dithiothreitol (DTT) and incubated at room temperature for 30 min with 1 unit of Klenow fragment (Takara Shuzo, Japan) in the presence of 2 mM each of dATP, dCTP, dGTP, and dTTP (Kojin Co., Ltd., Japan). Reaction was terminated by phenol extraction, followed by ethylether extraction and ethanol precipitation. DNAs were dissolved in TE buffer and cleaved with KpnI. The KpnI cleaved DNA fragments with the size of 2.6-3 kb were isolated by agarose gel electrophoresis and ligated with T4 DNA ligase to pHSG298 DNA cleaved with KpnI and HincII (Takara Shuzo). The ligation mixture was used for transformation of E. coli JM 109. Transformants were selected and confirmed as described previously. Plasmid DNA was prepared from one of the positive transformants and named pCCN176-3, the size of insert of which was estimated to be approximately 2.9 kb.

EXAMPLE 2 Determination of Nucleotide Sequence of the Gene Encoding Cephalosporin C Acylase of Pseudomonas diminuta N-176 2.1. Determination of Nucleotide Sequence

Restriction endonuclease mapping of the insert of pCCN176-3 was performed using restriction endonucleases EcoRV, Eco47III, MluI, NcoI, SacII, SalI, SmaI and XhoI (All from Takara Shuzo). Appropriate restriction endonuclease cleaved DNA fragments were subcloned into M13 phage vector and used for determination of the nucleotide sequences. Nucleotide sequence was determined by the dideoxy chain termination method (Cf. Sanger et al. Proc. Natl Acad. Sci., U.S.A. 74, 5463-5467 (1977)) using M13 sequencing kit (Toyobo Co., Ltd., Japan). The enzyme used was a modified T7 DNA polymerase Sequenase) and both 7-deaza dGTP and dITP were separately adopted as the nucleotide analog. Primers with the size of 20 bases corresponding to the sequence located in the middle of DNA fragments to be sequenced were also used in addition to the universal primer. Gel electrophoresis was performed at 2200 V for 5 or 13 hours using 5% polyacrylamide gel containing 7 M urea of 80 cm long. The nucleotide sequence of the insert of pCCN176-3 was shown in FIG. 2. One open reading frame of 2322 bp was recognized. This open reading frame was confirmed as the gene encoding the cephalosporin C acylase of Pseudomonas diminuta N-176 by following two results.

(1) The molecular weight of the cephalosporin C acylase (the sum of the molecular weights of α and β subunits) estimated by SDS-polyacrylamide gel electrophoresis was well coincided with that calculated from the deduced amino acid sequences for the open reading frame.

(2) The amino-terminal sequences of α and β subunits of the cephalosporin C acylase determined by gas-sequencing method (details will be described in the next Example) were identical with the amino acid sequences between codons at positions 1 and 18 and between codons at positions 239 and 253.

2.2. Comparison of the Amino Acid Sequence of the Cephalosporin C Acylase of Pseudomonas diminuta N-176 with that of Pseudomonas sp SE83

The amino acid sequence of the cephalosporin C acylase of Pseudomonas diminuta N-176 was compared with the known one of Pseudomonas sp. SE83 (Cf. K. Komatsu et al., Japanese Patent Application laid open No.61-152286, A. Matsuda et al.; J. Bacteriol. 169, 5815-5820 (1987)). the number of amino acid residues of CC acylase N-176 was identical with that of SE83 acylase. However, 50 amino acid residues and 198 nucleotide residues were recognized to be different between two acylases and their genes, respectively.

EXAMPLE 3 Purification of the Cephalosporin C Acylase of Pseudomonas diminuta N-176 from E. coli Transformant

An aqueous medium (3LB) (400 ml) containing 3% peptone (Difco Laboratories, U.S.A.), 1.5% yeast extract (Difco) and 0.5% NaCl was introduced into each of five 1 l flasks, sterilized at 121° C. for 20 min, and supplemented with 20 μg/ml kanamycin sulfate (Meiji Seika Co., Ltd., Japan) sterilized separately by filtration. To these media was inoculated a loopful of slant culture of E. coli JM109 possessing pCCN176-2, respectively and the organism was grown at 30° C. for 24 hours with shaking at 300 rpm on a rotary shaker. Meanwhile, an aqueous medium (120 l) comprising the same ingredients as mentioned above plus 0.2% fructose and 0.04 % adecanol (Asahi Denka Co., Ltd., Japan) was introduced into a 150 l jar fermenter, sterilized at 121° C. for 15 min and supplemented with 0.25 mg/ml IPTG sterilized separately by filtration. To the medium was inoculated whole volume of the cultured broth as obtained above, whereafter the organism was grown at 28° C. The fermentation was conducted by stirring the broth with a propeller equipment at 250 rpm and passing sterile air through the broth at a rate of one volume per volume of broth per minute. After 20 hours of cultivation, 10 g of IPTG and 1 kg of yeast extract, both of which were sterilized, were added to the culture broth and the organism was further grown for 2.5 hours. After the completion of the culture, the jar fermenter was cooled to 5° C. and the cells were harvested by continuous flow centrifugation at 20,000 rpm using a sharpless centrifuge. The cell pellet (approximately 2 kg) obtained was suspended in 20 mM Tris-HCl buffer (pH 8) at concentration of 100 g (wet weight) per l. To this suspension, DNase, RNase and lysozyme (all from Sigma Co., Ltd.) were added to make final concentrations of 40 μ/ml, 12.5 μg/ml and 1 mg/ml, respectively, and the mixture was incubated at room temperature for 2 hours with stirring. After incubation, the suspension was centrifuged at 10,000 g for 40 min and the resulting supernatant was dialyzed overnight against water. Meanwhile, the pellet was resuspended in 20 mM Tris-HCl buffer (pH 8) and disrupted in an ice-water bath by four pulses of 30 sec of sonication. The sonicated suspension was centrifuged at 10,000 g for 60 min and the resulting supernatant was also dialyzed overnight against water. Two dialyzed solutions were combined and subjected to another centrifugation at 10,000 g for. 40 min. The resulting supernatant was used as crude extract. The crude extract was applied onto a column of DEAE-Toyopearl 650H (Toso Co., Ltd., Japan) (15×15 cm) which had been equilibrated with 20 mM Tris HCl buffer (pH 8). After Washing the column with the same buffer, the column was eluted with 20 mM Tris-HCl buffer (pH 8) containing 100 mM NaCl. Fractions containing cephalosporin C acylase activity were pooled and adjusted to 60% saturation with ammonium sulfate, stirred for 30 min and centrifuged at 10,000 g for 20 min. The resulting pellet was dissolved in 20 mM phosphate buffer (pH 7), adjusted to 35% saturation with ammonium sulfate and applied onto a column of Toyopearl HW55F (Toso)(9.5×10 cm) equilibrated with the same buffer containing ammonium sulfate of 35% saturation. After washing with the same buffer, the column was eluted with 20 mM phosphate buffer (pH 7) containing ammonium sulfate of 20 % saturation. Fractions containing cephalosporin C acylase activity were pooled, adjusted to 60% saturation with ammonium sulfate, stirred for 30 min and centrifuged at 10,000 g for 20 min. The resulting pellet was dissolved in 20 mM phosphate buffer (pH 7), adjusted to 15% saturation with ammonium sulfate and applied onto an HPLC column of Butyl-Toyopearl 650s (Toso, 2.2 cm×20.0 cm) equilibrated with the same buffer containing ammonium sulfate of 15% saturation. Elution was performed with a linear gradient of ammonium sulfate (15 - 0% saturation) in 100 mM phosphate buffer (pH 8) at a flow rate of 4 ml/min over 120 min. Fractions containing cephalosporin C acylase activity were pooled, adjusted to 60% saturation with ammonium sulfate, stirred for 30 min and centrifuged at 10,000 g for 30 min. The pellet was dissolved in 20 mM Tris-HCl buffer (pH 8) and dialyzed against the same buffer. The dialysate was applied onto an HPLC column of TSK gel DEAE-Toyopearl 5PW Toso, 2.15 cm×15 cm) equilibrated with 20 mM Tris-HCl buffer (pH 8) and elution was performed with a linear gradient of NaCl (0-250 mM) in 20 mM Tris-HCl buffer (pH at a flow rate of 5 ml/min over 180 min. Fractions containing cephalosporin C acylase activity were pooled, dialyzed against 20 mM Tris-HCl buffer (pH 8) and applied again onto an HPLC column of TSK gel DEAE-Toyopearl 5PW (Toso, 0.75×7.5 cm). Elution was performed with a linear gradient of NaCl (0-250 mM) in 20 mM Tris-HCl buffer (pH 8) at a flow rate of 1 ml/min over 180 min. Fractions containing cephalosporin C acylase activity were pooled, dialyzed against 20 mM Tris-HCl buffer (pH 8) and used as the enzyme preparation. The total quantity of the final enzyme preparation was 10 mg and its purity was estimated to be 95%.

EXAMPLE 4 Characterization of the Cephalosporin C Acylase of Pseudomonas diminuta N-176 from an E. coli Transformant 4.1. Specific Enzyme Activity

The activity of the cephalosporin C acylase was determined by HPLC assay. Reaction mixtures (200 μl) containing 100 mM glycine buffer (pH 9), 1.25-40 mM Cephalosporin C Li and 19 μg of the enzyme is used for assay of cephalosporin C acylase, meanwhile for assay of GL-7ACA acylase activity, reaction mixture (200 μl) containing 100 mM glycine buffer (pH 9), 0.48-10.4 mM GL-7ACA and 0.5 μg of the enzyme is used. Reaction mixtures were incubated for 2 min at 37° C. and the reaction was terminated by addition of 200 μl of 4% acetic acid. Conditions for HPLC were the same as those described in Example 1.3. All assays used later in this section was HPLC method. Specific enzyme activity was expressed as unit per mg of protein. Protein concentrations were determined by Bio-Rad protein assay kit (Bio-Rad Co., Ltd., U.S.A.) with bovine serum albumin as a standard. Maximum specific enzyme activity (Vmax) and Michaelis constant (Km) were calculated from slope and intersection which were obtained by Lineweaver-Burk plot (Cf. M. Dixon and E. C. Webb, Enzymes, Longmans, London, 1958). Maximum specific enzyme activity of CC acylase N-176 was 100 and 3.1 units/mg for GL-7ACA and cephalosporin C, respectively. Km values of CC acylase N-176 was 2.6 and 4.8 mM for GL-7ACA and cephalosporin C.

4.2. Substrate Profile

Enzyme activity was determined by HPLC assay. Reaction mixture (200 μl) containing 100 mM glycine buffer (pH 9), 2 mg of a substrate and 20 μg of the enzyme was incubated at 50° C. for 2 min and the reaction was terminated by addition of 4% acetic acid. The relative enzyme activity was expressed as a percentage compared to the activity for GL-7ACA. To be noted, acylase activity for cephalosporin C was examined also by detecting the production of α-aminoadipic acid with the amino acid analyzer (Hitachi Co., Ltd., Japan).

                  TABLE 3                                                          ______________________________________                                         Substrate profile of CC acylase N-176                                          Substrates       Relative enzyme activity                                      ______________________________________                                         Succinyl 7ACA    32                                                            Glutaryl 7ACA    100                                                           Adipyl 7ACA      19                                                            Cephalosporin C  4                                                             N-Acetylcephalosporin C                                                                         0.1                                                           N-Benzyoylcephalo-                                                                              0.0003                                                        sporin C                                                                       Cephalothin      0.08                                                          ______________________________________                                          Note)                                                                          Succinyl 7ACA:                                                                 7(3-carboxypropionamido)-3-acetoxymethyl-3-cephem-4-carboxylic acid            Glutaryl 7ACA:                                                                 7(4-carboxybutanamdio)-3-acetoxymethyl-3-cephem-4-carboxylic acid              Adipyl 7ACA: 7(5-carboxypentanamido)-3-acetoxymethyl-3-cephem-4-carboxyli      acid                                                                     

4.3. Effect of Temperature (Cf. FIG. 3) a) Optimum Temperature

Reaction mixture (200 μl) containing 0.1M glycine buffer (pH 9), 2 mg of GL-7ACA and 2 μg of the enzyme were incubated for 2 min at various temperature from 25° to 60° C. The optimum temperature was 50° C.

b) Thermostability (Cf. FIG. 4)

One hundred μg/ml of the enzyme was treated in 0.1M glycine buffer (pH 9) at 50° C. for 6.5 hours. Aliquotes of the treated enzyme were sampled at 2, 3.5, 5, 6 and 6.5 hours later and the residual enzyme activities were assayed in the reaction mixture containing 0.1M glycine buffer (pH 9), 10 mg/ml of GL-7ACA and 10 μg/ml of the treated enzyme. The reaction was performed at 37° C. for 2 min.

4.4. Effect of pH (Cf. FIG. 5) a) Optimum pH

Reaction mixture (200 μl) containing 0.1M buffer (phosphate buffer between pH 6-8, Tris HCl buffer between pH 7-9 and glycine buffer between pH 8-10), 2 mg of GL-7ACA or 3.3 mg of cephalosporin C Li and 3 μg of the enzyme was used. The reaction was performed at 37° C. for 2 min. Optimum pH for the enzyme was 9.

b) pH profile of stability (Cf. FIG. 6)

One hundred μg/ml of the enzyme was treated at 50° C. for 1 hour in 0.1M buffer of various pH (phosphate buffer used for pH 6 and 7 and glycine buffer for pH 8, 9 and 10). The residual enzyme activity was assayed in the reaction mixture (200 μl) containing 0.1M glycine buffer (pH 9), 2 mg of GL-7ACA and 2 μg of the treated enzyme. Reaction was performed at 37° C. for 2 min.

4.5. Inhibition by Reaction Products (Cf. FIG. 7 and FIG. 8) a) Effect of Reaction Products on the Enzyme Activity of the Enzyme

Inhibitory activity of reaction products, namely 7-ACA, α-aminoadipic acid and glutaric acid on the enzyme activity of the enzyme was examined. The enzyme activity was assayed in the presence of various concentrations of 7-ACA, α-aminoadipic acid or glutaric acid. Reaction mixture (200 μl) containing besides the reaction product, 0.1M glycine buffer (pH 9), 2 mg of cephalosporin C Li and 200 μg of the enzyme is used for cephalosporin C acylase activity and reaction mixture containing 0.1M glycine buffer (pH 9), 200 μg of GL-7ACA and 5 μg of the enzyme is used for GL-7ACA acylase activity. The reaction was performed at 40° C. for 5 min for cephalosporin C acylase activity or at 37° C. for 1 min for GL-7ACA acylase activity.

b) Determination of Inhibition Constants (Ki) for Reaction Products

Enzyme activity was assayed in the presence of 7-ACA or glutaric acid. For determination of Ki of 7-ACA, reaction mixtures (200 μl) containing 0.1M glycine buffer (pH 9), 0.26-2.08 μmole of GL-7ACA, 0.182-1.0 μmole of 7-ACA and 1 μg of enzyme was incubated at 37° C. for 3 min. For determination of Ki of glutaric acid, reaction mixture (200 μl) containing 0.1M glycine buffer (pH 9), 0.096-2.08 μmole of GL-7ACA, 0.25-0.5 μmole of glutaric acid and 0.5 μg of the enzyme was incubated at 37° C. for 3 min. Lineweaver-Burk plots in the absence and presence of either inhibitor were shown to possess the same intersection at vertical axis, indication the mode of inhibition by either inhibitor was competitive. Ki values were calculated from the apparent Michaelis constants (Kmapp), Km and Vmax. Ki values of 7-ACA and glutaric acid were 1.4 and 2.5 mM, respectively.

c) Effect of Various Enzyme Inhibitors

Effect of p-chloromercuribenzoate (pCMB, Sigma Chemical Co., Ltd.), phenylmethylsulfonyl fluoride (PMSF, Sigma) and ethylenediaminetetraacetic acid (EDTA, Nacalai Tesque Inc., Japan) on the activity of CC acylase N-176 was examined as follows. Four μg of CC acylase N-176 was treated at 37° C. for 4 hours with 0.1 or 1.0 mM pCMB, 0.1, 1.0, 2.0 or 5.0 mM PMSF, or 1.0 or 5.0 mM EDTA in 200 μl of 0.1M glycine buffer (pH 9). Residual activity of the treated enzyme was assayed by adding 22 μl of GL-7ACA (100 mg/ml) as a substrate to the mixture The reaction was performed at 37° C. for 2 min. Residual activity was expressed as a percentage compared to the activity of the enzyme treated with blank solution.

                  TABLE 4                                                          ______________________________________                                         Effect of enzyme inhibitors on the activity of                                 CC acylase N-176                                                                          Concentration                                                                              Residual enzyme activity                                Inhibitors (mM)        (%)                                                     ______________________________________                                         pCMB       0.1         7.8                                                                1.0         4.6                                                     PMSF       0.1         96                                                                 1.0         91                                                                 2.0         79                                                                 5.0         62                                                      EDTA       1.0         91                                                                 5.0         73                                                      ______________________________________                                    

4.6 Determination of Isoelectric Point (pI)

Analytical isoelectric focusing of CC acylase N-176 was performed according to the method of Olson et al(Cf.FEMS Microbiol. Lett. 1, 157-162(1977)). Purified acylase preparation was applied on thin layer of 4% polyacrylamide gel containing 2% Ampholine pH range 3.5-10 (Pharmacia LKB Biotechnology, Sweden). The proteins were electrofocused for 2 hours at 100 volts using isoelectric focusing apparatus SJ-1071EC (ATTO Co., Ltd., Japan). After electrofocusing, the gel was stained with Coomassie Brilliant Blue R-250 and the isoelectric point was determined from the calibration curve made with pI markers (Pharmacia LKB Technology) which were run simultaneously with the sample. The pI value of CC acylase N-176 was estimated to be 4.5.

4.7. Determination of Molecular Weight by SDS-Poly-Acrylamide Gel Electrophoresis

Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis was performed by the procedure described by Laemmli (Cf. U.K.Laemmli; Nature 237, 680-685 (1970)). Egg white lysozyme (molecular weight 14,000), soybean trypsin inhibitor (21,000), bovine carbonic anhydrase (31,000), egg white ovalbumin (43,000), bovine serum albumin (68,000), rabbit muscle phosphorylase b (97,000) were purchased from BioRad Laboratories and used as molecular weight standards. The final preparation of CC acylase N-176 purified as described in Example 3 showed two discrete bands on SDS-gel electrophoresis, whose intensities were proportional to be corresponding molecular weights. The molecular weights of the two proteins calculated from their mobility on gel electrophoresis were 26,000 and 58,000. CC acylase N-176 was concluded to be composed of two heterologous subunits (α and β) of molecular weights 26,000 (α) and 58,000 (β).

4.8. Determination of Amino Acid Sequence

CC acylase N-176 is composed of two heterologous subunits α and β as described in Example 4.7 Each subunit was isolated by reversed phase HPLC. Column used was Cosmosil 5C4-300 (4.6 mm×5 cm, Nacalai tesque) Elution was performed with a linear gradient of acetonitrile (30% to 60%) in 0.1% trifluoroacetic acid at a flow rate of 1 ml/min over 20 min. The amino acid sequence of each subunit purified as above was determined by a gas-phase sequencer 470A (Applied Biosystems, .U.S.A.). The N-terminal amino acid sequences of α and β subunits were Thr-Met-Ala-Ala-Asn-Thr-Asp-Arg-Ala-Val-Leu-Gln-Ala-Ala-Leu-Pro-Pro-Leu (SEQ ID NO:1) and Ser-Asn-Asn-Trp-Ala-Val-Ala-Pro-Gly-Arg-Thr-Ala-Thr-Gly-Arg (SEQ ID NO:4), respectively.

The expression plasmid, pCCN176-2 obtained in the above Example was inserted into Escherichia coli JM109 and the resultant transformant as mentioned below has been deposited with one of the INTERNATIONAL DEPOSITORY AUTHORITY ON THE BUDAPEST TREATY, Fermentation Research Institute(FRI), Agency of Industrial Science and Technology at 1-3, Higashi 1 chome, Tsukubashi, Ibaraki-ken 305, Japan on August 7, 1990.

    ______________________________________                                         Organism             Deposit number                                            ______________________________________                                         Escheichia coli JM109 (pCCN176-2)                                                                   FERM BP-3047                                              ______________________________________                                    

    __________________________________________________________________________     SEQUENCE LISTING                                                               (1) GENERAL INFORMATION:                                                       (iii) NUMBER OF SEQUENCES: 3                                                   (2) INFORMATION FOR SEQ ID NO:1:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 18 amino acids                                                     (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: peptide                                                    (v) FRAGMENT TYPE: N-terminal                                                  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                        ThrMe tAlaAlaAsnThrAspArgAlaValLeuGlnAlaAlaLeuPro                              151015                                                                         ProLeu                                                                         (2) INFORMATION FOR SEQ ID NO:2:                                               (i) SEQUENCE CHARACTERISTICS:                                                  (A) LENGTH: 2847 base pairs                                                    (B) TYPE: nucleic acid                                                          (C) STRANDEDNESS: unknown                                                     (D) TOPOLOGY: unknown                                                          (ii) MOLECULE TYPE: DNA (genomic)                                              (ix) FEATURE:                                                                  (A) NAME/KEY: CDS                                                              (B) LOCATION: 483..2804                                                        (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                                        CCCGGGGATCTCGCAGACGGCTGGCGCGGTCCTGGCCAGCAATATGCGCAAGGCCGGCTT60                 CACGGTGGAAG AGCAGGTGATGGATTGGGGCACGGTGCTCGCCCGCCGGGCCAAGAAGGA120               CGGCTGGAGCGTTTTCCCGGTCTACGCCAACGGCATCGACATGATGTCGCCGCTGACGCA180                TTTCTACATCGGCAACAACTGCGTGAACTATGCGGGCTGGAGCTGCGACGCCGTCAT CAC240               CGAAAAGCTCGCCGCCTATGCCAAGGCGCCCGATCCGGCTACCCGCAAACGCATCGCGGC300                CGAAATCCAGGTCGAGGCCTACAAGGACACGCCCTCCGTGATGTGGGGCCAGTTCAGCCG360                GCCGGCGGGCTACCGCCTGCGCCTCAAGAACATC GTCCAGTCCAGCTTCCCGATCTTCTG420               GCAGCTCACGCTCGACGCGTGAGCTTGCCCAGATTCCGACAAGCAATGAGGTCCCGACGC480                GAATGACTATGGCGGCCAACACCGATCGCGCGGTCTTGCAGGCGGCG527                             MetThrM etAlaAlaAsnThrAspArgAlaValLeuGlnAlaAla                                 151015                                                                         CTGCCGCCGCTTTCCGGCAGCCTCCCCATTCCCGGATTGAGCGCGTCG575                            LeuProP roLeuSerGlySerLeuProIleProGlyLeuSerAlaSer                              202530                                                                         GTCCGCGTCCGGCGCGATGCCTGGGGCATCCCGCATATCAAGGCCTCG623                            ValArg ValArgArgAspAlaTrpGlyIleProHisIleLysAlaSer                              354045                                                                         GGCGAGGCCGATGCCTATCGGGCGCTGGGCTTCGTCCATTCGCAGGAC671                            GlyGluAla AspAlaTyrArgAlaLeuGlyPheValHisSerGlnAsp                              505560                                                                         CGTCTTTTCCAGATGGAGCTGACGCGTCGCAAGGCGCTGGGACGCGCG719                            ArgLeuPheGlnMe tGluLeuThrArgArgLysAlaLeuGlyArgAla                              657075                                                                         GCCGAATGGCTGGGCGCCGAGGCCGCCGAGGCCGATATCCTCGTGCGC767                            AlaGluTrpLeuGlyAlaGluA laAlaGluAlaAspIleLeuValArg                              80859095                                                                       CGGCTCGGAATGGAAAAAGTCTGCCGGCGCGACTTCGAGGCCTTGGGC815                            ArgLeuGlyMetGluLys ValCysArgArgAspPheGluAlaLeuGly                              100105110                                                                      GTCGAGGCGAAGGACATGCTGCGGGCTTATGTCGCCGGCGTGAACGCA863                            ValGluAlaLysAspMet LeuArgAlaTyrValAlaGlyValAsnAla                              115120125                                                                      TTCCTGGCTTCCGGTGCTCCCCTGCCTGTCGAATACGGATTGCTCGGA911                            PheLeuAlaSerGlyAlaPr oLeuProValGluTyrGlyLeuLeuGly                              130135140                                                                      GCAGAGCCGGAGCCCTGGGAGCCTTGGCACAGCATCGCGGTGATGCGC959                            AlaGluProGluProTrpGluProT rpHisSerIleAlaValMetArg                              145150155                                                                      CGGCTGGGCCTGCTTATGGGTTCGGTGTGGTTCAAGCTCTGGCGGATG1007                           ArgLeuGlyLeuLeuMetGlySerValTrpPhe LysLeuTrpArgMet                              160165170175                                                                   CTGGCGCTGCCGGTGGTCGGAGCCGCGAATGCGCTGAAGCTGCGCTAT1055                           LeuAlaLeuProValValGlyAlaAlaAsn AlaLeuLysLeuArgTyr                              180185190                                                                      GACGATGGCGGCCGGGATTTGCTCTGCATCCCGCCGGGCGCCGAAGCC1103                           AspAspGlyGlyArgAspLeuLeuCysIl eProProGlyAlaGluAla                              195200205                                                                      GATCGGCTCGAGGCGGATCTCGCGACCCTGCGGCCCGCGGTCGATGCG1151                           AspArgLeuGluAlaAspLeuAlaThrLeuA rgProAlaValAspAla                              210215220                                                                      CTGCTGAAGGCGATGGGCGGCGATGCCTCCGATGCTGCCGGCGGCGGC1199                           LeuLeuLysAlaMetGlyGlyAspAlaSerAspAla AlaGlyGlyGly                              225230235                                                                      AGCAACAACTGGGCGGTCGCTCCGGGCCGCACGGCGACCGGCAGGCCG1247                           SerAsnAsnTrpAlaValAlaProGlyArgThrAlaThrGlyArg Pro                              240245250255                                                                   ATCCTCGCGGGCGATCCGCATCGCGTCTTCGAAATCCCGGGCATGTAT1295                           IleLeuAlaGlyAspProHisArgValPheGluIleProGl yMetTyr                              260265270                                                                      GCGCAGCATCATCTGGCCTGCGACCGGTTCGACATGATCGGCCTGACC1343                           AlaGlnHisHisLeuAlaCysAspArgPheAspMetIleG lyLeuThr                              275280285                                                                      GTGCCGGGCGTGCCGGGCTTCCCGCACTTCGCGCATAACGGCAAGGTC1391                           ValProGlyValProGlyPheProHisPheAlaHisAsnGly LysVal                              290295300                                                                      GCCTATTGCGTCACCCATGCCTTCATGGACATCCACGATCTCTATCTC1439                           AlaTyrCysValThrHisAlaPheMetAspIleHisAspLeuTyrLeu                               305310315                                                                      GAGCAGTTCGCGGGGGAGGGCCGCACTGCGCGGTTCGGCAACGATTTC1487                           GluGlnPheAlaGlyGluGlyArgThrAlaArgPheGlyAsnAspPhe                               320 325330335                                                                  GAGCCCGTCGCCTGGAGCCGGGACCGTATCGCGGTCCGGGGTGGCGCC1535                           GluProValAlaTrpSerArgAspArgIleAlaValArgGlyGlyAla                                340345350                                                                     GATCGCGAGTTCGATATCGTCGAGACGCGCCATGGCCCGGTTATCGCG1583                           AspArgGluPheAspIleValGluThrArgHisGlyProValIleAla                                355360365                                                                     GGCGATCCGCGCGATGGCGCAGCGCTCACGCTGCGTTCGGTCCAGTTC1631                           GlyAspProArgAspGlyAlaAlaLeuThrLeuArgSerValGlnPhe                                370375380                                                                     GCCGAGACCGATCTGTCCTTCGACTGCCTGACGCGGATGCCGGGCGCA1679                           AlaGluThrAspLeuSerPheAspCysLeuThrArgMetProGlyAla                               385 390395                                                                     TCGACCGTGGCCCAGCTCTACGACGCGACGCGCGGCTGGGGCCTGATC1727                           SerThrValAlaGlnLeuTyrAspAlaThrArgGlyTrpGlyLeuIle                               400405 410415                                                                  GACCATAACCTCGTCGCCGGGGATGTCGCGGGCTCGATCGGCCATCTG1775                           AspHisAsnLeuValAlaGlyAspValAlaGlySerIleGlyHisLeu                               420 425430                                                                     GTCCGCGCCCGCGTTCCGTCCCGTCCGCGCGAAAACGGCTGGCTGCCG1823                           ValArgAlaArgValProSerArgProArgGluAsnGlyTrpLeuPro                               435 440445                                                                     GTGCCGGGCTGGTCCGGCGAGCATGAATGGCGGGGCTGGATTCCGCAC1871                           ValProGlyTrpSerGlyGluHisGluTrpArgGlyTrpIleProHis                               450 455460                                                                     GAGGCGATGCCGCGCGTGATCGATCCGCCGGGCGGCATCATCGTCACG1919                           GluAlaMetProArgValIleAspProProGlyGlyIleIleValThr                               465470 475                                                                     GCGAATAATCGCGTCGTGGCCGATGACCATCCCGATTATCTCTGCACC1967                           AlaAsnAsnArgValValAlaAspAspHisProAspTyrLeuCysThr                               480485 490495                                                                  GATTGCCATCCGCCCTACCGCGCCGAGCGCATCATGAAGCGCCTGGTC2015                           AspCysHisProProTyrArgAlaGluArgIleMetLysArgLeuVal                               500 505510                                                                     GCCAATCCGGCTTTCGCCGTCGACGATGCCGCCGCGATCCATGCCGAT2063                           AlaAsnProAlaPheAlaValAspAspAlaAlaAlaIleHisAlaAsp                               5155 20525                                                                     ACGCTGTCGCCCCATGTCGGGTTGCTGCGCCGGAGGCTCGAGGCGCTT2111                           ThrLeuSerProHisValGlyLeuLeuArgArgArgLeuGluAlaLeu                               530535 540                                                                     GGAGCCCGCGACGACTCCGCGGCCGAAGGGCTGAGGCAGATGCTCGTC2159                           GlyAlaArgAspAspSerAlaAlaGluGlyLeuArgGlnMetLeuVal                               545550 555                                                                     GCCTGGGACGGCCGCATGGATGCGGCTTCGGAGGTCGCGTCTGCCTAC2207                           AlaTrpAspGlyArgMetAspAlaAlaSerGluValAlaSerAlaTyr                               560565570 575                                                                  AATGCGTTCCGCAGGGCGCTGACGCGGCTGGTGACGGACCGCAGCGGG2255                           AsnAlaPheArgArgAlaLeuThrArgLeuValThrAspArgSerGly                               580585 590                                                                     CTGGAGCAGGCGATATCGCATCCCTTCGCGGCTGTCGCGCCGGGCGTC2303                           LeuGluGlnAlaIleSerHisProPheAlaAlaValAlaProGlyVal                               595600 605                                                                     TCACCGCAAGGCCAGGTCTGGTGGGCCGTGCCGACCCTGCTGCGCGAC2351                           SerProGlnGlyGlnValTrpTrpAlaValProThrLeuLeuArgAsp                               610615620                                                                      GACGATGCCGGAATGCTGAAGGGCTGGAGCTGGGACCAGGCCTTGTCT2399                           AspAspAlaGlyMetLeuLysGlyTrpSerTrpAspGlnAlaLeuSer                               625630635                                                                      GAGGCC CTCTCGGTCGCGTCGCAGAACCTGACCGGGCGAAGCTGGGGC2447                          GluAlaLeuSerValAlaSerGlnAsnLeuThrGlyArgSerTrpGly                               640645650655                                                                   GAA GAGCATCGGCCGCGCTTCACGCATCCGCTTGCCACGCAATTCCCG2495                          GluGluHisArgProArgPheThrHisProLeuAlaThrGlnPhePro                               660665670                                                                      GC CTGGGCGGGGCTGCTGAATCCGGCTTCCCGTCCGATCGGTGGCGAT2543                          AlaTrpAlaGlyLeuLeuAsnProAlaSerArgProIleGlyGlyAsp                               675680685                                                                      GGCG ATACCGTGCTGGCGAACGGGCTCGTCCCGTCAGCCGGGCCGCAG2591                          GlyAspThrValLeuAlaAsnGlyLeuValProSerAlaGlyProGln                               690695700                                                                      GCGACCTAT GGTGCCCTGTCGCGCTACGTCTTCGATGTCGGCAATTGG2639                          AlaThrTyrGlyAlaLeuSerArgTyrValPheAspValGlyAsnTrp                               705710715                                                                      GACAATAGCCGCTGGGTC GTCTTCCACGGCGCCTCCGGGCATCCGGCC2687                          AspAsnSerArgTrpValValPheHisGlyAlaSerGlyHisProAla                               720725730735                                                                   AGCGCCCATTATGC CGATCAGAATGCGCCCTGGAGCGACTGTGCGATG2735                          SerAlaHisTyrAlaAspGlnAsnAlaProTrpSerAspCysAlaMet                               740745750                                                                      GTGCCGATGCTCT ATAGCTGGGACAGGATCGCGGCAGAGGCCGTGACG2783                          ValProMetLeuTyrSerTrpAspArgIleAlaAlaGluAlaValThr                               755760765                                                                      TCGCAGGAACTCGTC CCGGCCTGAGGGCCGGGCCTGTTGTCAGCCTGCCGC2834                       SerGlnGluLeuValProAla                                                          770                                                                            AGCTCTCTTCGGC2847                                                              (2) INFORMATION FOR SEQ ID NO:3:                                               (i) SEQUENCE CHARACTERISTICS:                                                   (A) LENGTH: 774 amino acids                                                   (B) TYPE: amino acid                                                           (D) TOPOLOGY: linear                                                           (ii) MOLECULE TYPE: protein                                                    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                        MetThrMetAlaAlaAsnThrAspArgAlaValLeuGlnAlaAlaLeu                               1510 15                                                                        ProProLeuSerGlySerLeuProIleProGlyLeuSerAlaSerVal                               202530                                                                         ArgValArgArgAspAlaTrpGlyIleProHisIleLysAlaSerGly                                354045                                                                        GluAlaAspAlaTyrArgAlaLeuGlyPheValHisSerGlnAspArg                               505560                                                                         LeuPheGlnMetGluLeuThrArgArg LysAlaLeuGlyArgAlaAla                              65707580                                                                       GluTrpLeuGlyAlaGluAlaAlaGluAlaAspIleLeuValArgArg                               8590 95                                                                        LeuGlyMetGluLysValCysArgArgAspPheGluAlaLeuGlyVal                               100105110                                                                      GluAlaLysAspMetLeuArgAlaTyrValAlaGlyValAs nAlaPhe                              115120125                                                                      LeuAlaSerGlyAlaProLeuProValGluTyrGlyLeuLeuGlyAla                               130135140                                                                      GluProGluProTrp GluProTrpHisSerIleAlaValMetArgArg                              145150155160                                                                   LeuGlyLeuLeuMetGlySerValTrpPheLysLeuTrpArgMetLeu                               165 170175                                                                     AlaLeuProValValGlyAlaAlaAsnAlaLeuLysLeuArgTyrAsp                               180185190                                                                      AspGlyGlyArgAspLeuLeuCysIlePro ProGlyAlaGluAlaAsp                              195200205                                                                      ArgLeuGluAlaAspLeuAlaThrLeuArgProAlaValAspAlaLeu                               210215220                                                                      LeuL ysAlaMetGlyGlyAspAlaSerAspAlaAlaGlyGlyGlySer                              225230235240                                                                   AsnAsnTrpAlaValAlaProGlyArgThrAlaThrGlyArgProIle                                245250255                                                                     LeuAlaGlyAspProHisArgValPheGluIleProGlyMetTyrAla                               260265270                                                                      GlnHisHisLeuAlaCys AspArgPheAspMetIleGlyLeuThrVal                              275280285                                                                      ProGlyValProGlyPheProHisPheAlaHisAsnGlyLysValAla                               290295 300                                                                     TyrCysValThrHisAlaPheMetAspIleHisAspLeuTyrLeuGlu                               305310315320                                                                   GlnPheAlaGlyGluGlyArgThrAlaArgPheGlyAsnAspPhe Glu                              325330335                                                                      ProValAlaTrpSerArgAspArgIleAlaValArgGlyGlyAlaAsp                               340345350                                                                      ArgGluP heAspIleValGluThrArgHisGlyProValIleAlaGly                              355360365                                                                      AspProArgAspGlyAlaAlaLeuThrLeuArgSerValGlnPheAla                               3703 75380                                                                     GluThrAspLeuSerPheAspCysLeuThrArgMetProGlyAlaSer                               385390395400                                                                   ThrValAlaGlnLeuTyrAspAlaThrArgGly TrpGlyLeuIleAsp                              405410415                                                                      HisAsnLeuValAlaGlyAspValAlaGlySerIleGlyHisLeuVal                               420425 430                                                                     ArgAlaArgValProSerArgProArgGluAsnGlyTrpLeuProVal                               435440445                                                                      ProGlyTrpSerGlyGluHisGluTrpArgGlyTrpIleProHisGlu                               450 455460                                                                     AlaMetProArgValIleAspProProGlyGlyIleIleValThrAla                               465470475480                                                                   AsnAsnArgValValAlaAspA spHisProAspTyrLeuCysThrAsp                              485490495                                                                      CysHisProProTyrArgAlaGluArgIleMetLysArgLeuValAla                               500505 510                                                                     AsnProAlaPheAlaValAspAspAlaAlaAlaIleHisAlaAspThr                               515520525                                                                      LeuSerProHisValGlyLeuLeuArgArgArgLeuGluAlaLeu Gly                              530535540                                                                      AlaArgAspAspSerAlaAlaGluGlyLeuArgGlnMetLeuValAla                               545550555560                                                                   TrpAspGlyAr gMetAspAlaAlaSerGluValAlaSerAlaTyrAsn                              565570575                                                                      AlaPheArgArgAlaLeuThrArgLeuValThrAspArgSerGlyLeu                               580 585590                                                                     GluGlnAlaIleSerHisProPheAlaAlaValAlaProGlyValSer                               595600605                                                                      ProGlnGlyGlnValTrpTrpAlaValProThrL euLeuArgAspAsp                              610615620                                                                      AspAlaGlyMetLeuLysGlyTrpSerTrpAspGlnAlaLeuSerGlu                               625630635640                                                                    AlaLeuSerValAlaSerGlnAsnLeuThrGlyArgSerTrpGlyGlu                              645650655                                                                      GluHisArgProArgPheThrHisProLeuAlaThrGlnPheProAla                                660665670                                                                     TrpAlaGlyLeuLeuAsnProAlaSerArgProIleGlyGlyAspGly                               675680685                                                                      AspThrValLeuAlaAsnGlyLe uValProSerAlaGlyProGlnAla                              690695700                                                                      ThrTyrGlyAlaLeuSerArgTyrValPheAspValGlyAsnTrpAsp                               705710715 720                                                                  AsnSerArgTrpValValPheHisGlyAlaSerGlyHisProAlaSer                               725730735                                                                      AlaHisTyrAlaAspGlnAsnAlaProTrpSerAspCysAlaM etVal                              740745750                                                                      ProMetLeuTyrSerTrpAspArgIleAlaAlaGluAlaValThrSer                               755760765                                                                      GlnGluLeuVal ProAla                                                            770                                                                        

We claim:
 1. An isolated and purified DNA consisting essentially of a nucleotide sequence which encodes a cephalosporin C acylase having the following characteristics:(a) enzymatically converts cephalosporin C, glutaryl 7-ACA, adipyl 7-ACA, succinyl 7-ACA, N-acetylcephalosporin C, N-benzoylcephalosporin C and cephalothin into 7-aminocephalosporanic acid, (b) contains (i) an α-subunit having a molecular weight of 26,000 daltons as determined by SDS-PAGE and (ii) a β-subunit having a molecular weight of 58,000 daltons as determined by SDS-PAGE, (c) said α-subunit has an N-terminal amino acid sequence (SEQ ID NO:1) of the formula: ##STR3##
 2. The DNA of claim 1, which has the nucleotide sequence (SEQUENCE ID NO:2).
 3. An expression vector which comprises the DNA of claim 1 or
 2. 4. A host cell transformed by the expression vector of claim
 3. 5. The host cell of claim 4 which is an Escherichia coli.
 6. A process for producing cephalosporin C acylase, which comprises culturing the host cell of claim 4 or 5 in an aqueous nutrient medium and recovering the cephalosporin C acylase from.
 7. A process for preparing a compound of the formula (I): ##STR4## wherein R¹ is acetoxy, hydroxy or hydrogen or its salt, which comprises contacting a compound of the formula (II): ##STR5## wherein R¹ is the same as defined above, R² is carboxylic acyl or its salt with the cephalosporin C acylase expressed by the transformant of claim 4 or
 5. 